Related Experiment Video
Updated: Jul 23, 2026

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models
Published on: October 20, 2017
[Neurolytic blocks for cancer pain--still a useful therapeutic strategy]
Ulf E Kongsgaard1, Steinar Bjørgo, Markus Hauser
1Anestesiavdelingen, Det Norske Radiumhospital, Oslo. u.e.kongsgaard@klinmed.uio.no
Background:
Patients with advanced cancer may present complex sets of symptoms, of which pain is the most prevalent. In addition to systemic pharmacological therapy for pain management, neurolytic blocks are also effective in controlling cancer pain in selected patients.
Method:
Various neurolytic blocks used in the treatment of cancer pain are reviewed.
Results:
Several studies have documented the efficacy of neurolytic blocks in reducing pain intensity and opioid consumption, although good prospective, randomized controlled trials are scarce. The narrow risk-benefit ratio associated with neurolysis techniques requires knowledge of the complications associated with the different neurolytic blocks in order to minimise undesirable effects.
Interpretation:
Interventional techniques continue to play an important role in the management of cancer pain. The quality of the neurolytic blocks improves when they are performed image-guided in collaboration with an interventional radiologist. These blocks should never be considered an isolated treatment, but as a component of a comprehensive therapeutic strategy.
Related Concept Videos
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Local Anesthetics: Differential Sensitivity of Nerve Fibers
Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia
Analgesia and Pain Management
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

